RAFAEL HOLDINGS, INC. Fair Value, Recurring Basis, Unobservable Input Reconciliation, Asset (Liability), Gain (Loss), OCI
RAFAEL HOLDINGS, INC. (RFL) reported Fair Value, Recurring Basis, Unobservable Input Reconciliation, Asset (Liability), Gain (Loss), OCI of -$79.00 thousand for the 12-month period ending 2023-07-31, per its 10-K filed 2023-10-30.
Discontinued › Income Statement › Other Income
us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetLiabilityGainLossOci · last filed 2023-10-30
- RAFAEL HOLDINGS, INC. fair value, recurring basis, unobservable input reconciliation, asset (liability), gain (loss), oci for fiscal 2023 was -$79.00K.
| Period end | Fair Value, Recurring Basis, Unobservable Input Reconciliation, Asset (Liability), Gain (Loss), OCI 12 month |
|---|---|
| 2023-07-31 | -$79.00K 10-K · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |